Brand Reference: Rapamune
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sirolimus (Intermittent Longevity Protocol) RxNorm Concept ID | 35302 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.9400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $168.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $24.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $48.00 / mo | 34 Zero-PHI Verified Patient Logs |
Binds cytosolic FK506-binding protein 12 (FKBP12) to form an allosteric complex that inhibits mechanistic Target of Rapamycin Complex 1 (mTORC1) without chronic mTORC2 suppression when pulsed weekly, upregulating ULK1-driven macroautophagy, clearing misfolded aggregates, and rejuvenating hematopoietic stem-cell function.
For self-pay patients filling Sirolimus (Intermittent Longevity Protocol) (NDC 00008-0923-55), direct wholesale and telehealth fulfillment drops monthly spend from $168.00 retail to $24.80 (85% savings against a $2.9400 CMS pharmacy acquisition baseline).
Clinical clearance of Sirolimus (Intermittent Longevity Protocol) (Allosteric mTORC1 Kinase Inhibitor / Geroprotector) relies on extensive intestinal and hepatic cyp3a4 metabolism plus p-glycoprotein efflux with a 57–63 hours half-life; patients absorbing at 14%–18% tablet (enhanced by high-fat meal) bioavailability typically observe target onset around 1–2 hours cmax; weekly trough washout before next pulse.
FDA clinical labeling for Sirolimus (Intermittent Longevity Protocol) restricts administration in active systemic bacterial or fungal infection; concurrent strong cyp3a4 inhibitors (ketoconazole/grapefruit) without dose reduction; impaired surgical wound healing window across 2 mg PO once weekly, 5 mg PO once weekly, 6 mg PO once weekly (pulsed geroprotective schedule), with self-reported patient tracking dominated by aphthous mouth ulcer (transient) (19% of reports), mild ldl-c bump (14% of reports), fasting glucose +4 mg/dl (9% of reports).
Across 34 verified cash-pay logs, Sirolimus (Intermittent Longevity Protocol) achieves a 91.60% Worth-It rating with out-of-pocket spend averaging $48.00/mo versus $168.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 2 mg PO once weekly for Sirolimus (Intermittent Longevity Protocol); monthly out-of-pocket dropped to $21.82 compared with $168.00 retail.
Completed 10 weeks on Sirolimus (Intermittent Longevity Protocol) (5 mg PO once weekly). Zero notable side effects on steady dosing.
Consistent biomarker response on 6 mg PO once weekly (pulsed geroprotective schedule) Sirolimus (Intermittent Longevity Protocol) sourced via Local Pharmacy ($28.77/mo cash pay without insurance prior authorization).